Financial Performance - Alcidion achieved a record FY25 revenue of $40.8 million, a 10% increase compared to the prior corresponding period (pcp)[31] - The company's Annual Recurring Revenue (ARR) as of June 30, 2025, reached $28.5 million, up 31% from the previous year[31] - Underlying EBITDA for FY25 was $5.1 million, a significant improvement from the $3.4 million loss in FY24[31] - Alcidion reported positive operating cash flow of $5.8 million in FY25, a substantial turnaround from the $7.1 million loss in FY24[31] - The company's balance sheet shows a strong cash position of $17.7 million as of June 2025[15] Contract Wins and Growth Drivers - New Total Contract Value (TCV) reached $73.8 million, a 109% increase compared to pcp, driven by a milestone $39 million+ EPR contract[31] - Alcidion secured a significant contract with North Cumbria NHS Trust (UK) for a new EPR solution valued at over $39.0 million over 10 years[31, 55] - The company has $34 million in contracted revenue to be recognized in FY26, providing a solid foundation for future growth[31] Strategic Focus and Outlook - Alcidion is focusing on Flow & EPR opportunities, module expansion, adjacent markets, and geographical expansion to drive growth[31] - The company is targeting to be EBITDA positive and deliver positive operating cash flow in FY26[76] - Alcidion is exploring entry into new geographies, including Canada, Saudi Arabia, and UAE[77]